https://vital.seals.ac.za/vital/access/manager/Index ${session.getAttribute("locale")} 5 https://vital.seals.ac.za/vital/access/manager/Repository/vital:38538 Wed 12 May 2021 23:00:38 SAST ]]> https://vital.seals.ac.za/vital/access/manager/Repository/vital:25450 Wed 12 May 2021 22:39:29 SAST ]]> https://vital.seals.ac.za/vital/access/manager/Repository/vital:24014 Wed 12 May 2021 16:35:23 SAST ]]> https://vital.seals.ac.za/vital/access/manager/Repository/vital:26094 Thu 29 Sep 2022 14:21:25 SAST ]]> https://vital.seals.ac.za/vital/access/manager/Repository/vital:27799 Thu 29 Sep 2022 14:18:31 SAST ]]> https://vital.seals.ac.za/vital/access/manager/Repository/vital:29924 0.05), development or the active metabolic (P > 0.05) or metabolic scope (P > 0.05) of fish in the three treatments throughout the study. However, the standard metabolic rate was significantly higher in the year 2068 treatment but only at the flexion/post-flexion stage which could be attributed to differences in developmental rates (including the development of the gills) between the 2068 and the other two treatments. Overall, the metabolic scope was narrowest in the 2090 treatment, but varied according to life stage. Although not significantly different, metabolic scope in the 2090 treatment was noticeably lower at the flexion stage compared to the other two treatments, and the development appeared slower, suggesting that this could be the stage most prone to OA. The study concluded that, in isolation, OA levels predicted to occur between 2050 and 2090 will not negatively affect size-at-hatch, growth, development, and metabolic responses of larval A. japonicus up to 22 DAH (flexion/post-flexion stage). Taken together with the previous studies of the same species, the tipping point of tolerance (where negative impacts will begin) in larvae of the species appears to be between the years 2090 and 2100.]]> Thu 29 Sep 2022 12:56:05 SAST ]]>